These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38829515)

  • 41. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging agents for the treatment and prevention of stroke: progress in clinical trials.
    Safouris A; Magoufis G; Tsivgoulis G
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1025-1035. PubMed ID: 34555978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.
    Eliasson B; Ekelund J; Holmberg CN; Wolden ML; Matthiessen KS; James S
    Eur J Prev Cardiol; 2023 May; 30(7):546-551. PubMed ID: 36567502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
    Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
    Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
    Ray KK; Raal FJ; Kallend DG; Jaros MJ; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Lawrence D; Friedman A; Garcia Conde L; Wright RS;
    Eur Heart J; 2023 Jan; 44(2):129-138. PubMed ID: 36331326
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
    McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
    Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
    Gibson CM; Kastelein JJP; Phillips AT; Aylward PE; Yee MK; Tendera M; Nicholls SJ; Pocock S; Goodman SG; Alexander JH; Lincoff AM; Bode C; Duffy D; Heise M; Berman G; Mears SJ; Tricoci P; Deckelbaum LI; Steg PG; Ridker P; Mehran R
    Am Heart J; 2021 Jan; 231():121-127. PubMed ID: 33065120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Bansilal S; Bhatt DL; Leiter LA; McGuire DK; Wilding JP; Gause-Nilsson IA; Langkilde AM; Johansson PA; Sabatine MS
    Am Heart J; 2018 Jun; 200():83-89. PubMed ID: 29898853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.
    Makover ME; Shapiro MD; Toth PP
    Am J Prev Cardiol; 2022 Dec; 12():100371. PubMed ID: 36124049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inclisiran for the Treatment of Hyperlipidemia and for Atherosclerotic Cardiovascular Disease Risk Reduction: A Narrative Review.
    Cowart K; Singleton J; Carris NW
    Clin Ther; 2023 Nov; 45(11):1099-1104. PubMed ID: 37451914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction.
    Sakhuja S; Bittner VA; Brown TM; Farkouh ME; Levitan EB; Safford MM; Woodward M; Chen L; Sun R; Dhalwani N; Jones J; Kalich B; Exter J; Muntner P; Rosenson RS; Colantonio LD
    Cardiovasc Drugs Ther; 2024 Oct; 38(5):937-945. PubMed ID: 37052867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).
    Yeboah J; Sillau S; Delaney JC; Blaha MJ; Michos ED; Young R; Qureshi WT; McClelland R; Burke GL; Psaty BM; Herrington DM
    Am Heart J; 2015 Mar; 169(3):387-395.e3. PubMed ID: 25728729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline.
    Alanaeme CJ; Bittner V; Brown TM; Colantonio LD; Dhalwani N; Jones J; Kalich B; Exter J; Jackson EA; Levitan EB; Poudel B; Wang Z; Woodward M; Muntner P; Rosenson RS
    Am Heart J Plus; 2022 Sep; 21():. PubMed ID: 37168932
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.